The PDHA1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line. This product features disruption of the PDHA1 gene, encoding the pyruvate dehydrogenase E1 alpha 1 subunit, through CRISPR/Cas9-mediated gene disruption. As a polyclonal pool, these cells contain a heterogeneous mix of PDHA1 knockout alleles, providing a robust loss-of-function model for studying pyruvate metabolism and its downstream effects in a B-cell context. The knockout model enables investigation of PDHA1-dependent metabolic processes without the need for clonal selection, preserving cellular diversity and phenotypic variability that can be exploited in functional assays.
The Raji cell line is an Epstein-Barr virus-positive Burkitt lymphoma-derived B lymphocyte line widely used in immunology and cancer research. As antibody-producing B cells, Raji cells are engaged in immune responses and have been instrumental in studying B-cell malignancies, viral oncogenesis, and cell signaling. Their metabolic profile is characterized by active glycolysis and glutaminolysis, typical of many lymphoma cells, making them a relevant model to investigate metabolic reprogramming associated with the Warburg effect. The use of Raji cells as a host for PDHA1 knockout allows exploration of how pyruvate oxidation contributes to B-cell lymphomagenesis and immune cell function.
PDHA1 encodes the E1 alpha subunit of the pyruvate dehydrogenase complex (PDC), which catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, a critical step linking glycolysis to the tricarboxylic acid (TCA) cycle. PDHA1 activity is tightly regulated by upstream kinases PDK1?C4, which phosphorylate and inactivate the complex, and by phosphatases PDP1 and PDP2, which reactivate it. Insulin and the transcription factor HIF-1?? also modulate PDHA1 expression and activity. Downstream, PDHA1 generates acetyl-CoA for the TCA cycle, fatty acid synthesis, and cholesterol synthesis, influencing the NADH/NAD+ ratio. PDHA1 interacts with PDHB, PDHX, DLAT, and DLD to form the PDC holoenzyme. Disruption of PDHA1 impairs mitochondrial pyruvate utilization, shifting cells toward reliance on alternative substrates such as glutamine and fatty acids to meet bioenergetic and biosynthetic demands.
In Raji B lymphocytes, PDHA1 knockout disrupts the normal flow of glycolytic pyruvate into the TCA cycle, mimicking metabolic conditions such as pyruvate dehydrogenase deficiency. This model is particularly relevant for studying the metabolic adaptations of B-cell lymphomas, which often rely on aerobic glycolysis and glutaminolysis. Loss of PDHA1 forces these cells to engage alternative metabolic pathways, potentially revealing vulnerabilities that can be targeted therapeutically. The polyclonal nature of the knockout population allows for the observation of a range of phenotypes, reflecting the heterogeneity of metabolic responses and enhancing the robustness of functional assays. This system can be used to study the impact of PDHA1 loss on cell proliferation, survival under metabolic stress, and sensitivity to chemotherapeutic agents.
These polyclonal PDHA1 knockout Raji cells are suitable for investigating pyruvate metabolism in B-cell malignancies, evaluating metabolic flux using Seahorse analyzers, and measuring lactate production or cell proliferation under pyruvate deprivation. Researchers can employ Western blotting or RT-qPCR to confirm PDHA1 disruption, perform pyruvate dehydrogenase activity assays, and screen for PDH activators or metabolic inhibitors. The model supports studies on the role of PDHA1 in the Warburg effect, immune cell metabolism, and metabolic disorders like Leigh syndrome. Additionally, these cells facilitate investigation of PDHA1 interactions with regulatory partners like PDK1 and PDP1 and assessment of compounds targeting mitochondrial metabolism. For further information, please contact Ascent Research.
